Apoptosis

 Table of Content
1. SCOPE AND METHODOLOGY	1
2. REPORT SYNOPSIS	3
Foreword	3
APOPTOSIS	3
History – Apoptosis	3
Morphology of Apoptosis	4
Component of Apoptosis Pathway	4
Apoptosis Reagents	5
The TUNEL Assay	5
Annexin-V	5
Synaptotagmin	5
FDG	5
Segmentation of Apoptosis	6
Exhibit 1. Segmentation of Global Apoptosis Related Products Market by Molecular Pathways and Therapeutic Areas	6
Exhibit 2. Segmentation of Global Apoptosis Market by Imaging/Detection Technologies for Cancer	6
2.3 Apoptosis - Global Market Analysis	7
Exhibit 3. Apoptosis Related Products – Global Market Estimations & Predictions (2005-2020) in US$ Million	7
Exhibit 4. List of Major Global Companies	8
3. MARKET DYNAMICS	10
3.1 Market Overview	10
3.2 Global Apoptosis Related Products Market	10
Exhibit 5. Apoptosis Related Products – Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	11
Exhibit 6. Apoptosis Related Products – Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	12
3.3 North American Apoptosis Related Products Market	13
Exhibit 7. Apoptosis Related Products – North American Market Estimations & Predictions (2005 - 2020) by Country for United States and Canada in US$ Million	13
Exhibit 8. Apoptosis Related Products – North American Market Shares (2010, 2015 & 2020) by Country for United States and Canada	14
3.3 (I) United States Apoptosis Related Products Market	14
3.3 (II) Canadian Apoptosis Related Products Market	14
Exhibit 9. List of Major North American Companies	14
3.4 European Apoptosis Related Products Market	16
Exhibit 10. Apoptosis Related Products – European Market Estimations & Predictions (2005 - 2020) by Country for Germany, United Kingdom, France, Russia and Rest of Europe in US$ Million	16
Exhibit 11. Apoptosis Related Products – European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, France, Russia and Rest of Europe	17
3.4 (I) German Apoptosis Related Products Market	17
3.4 (II) UK Apoptosis Related Products Market	17
3.4 (III) French Apoptosis Related Products Market	17
3.4 (IV) Russian Apoptosis Related Products Market	17
Exhibit 12. List of Major European Companies	18
3.5 Asia-Pacific Apoptosis Related Products Market	19
Exhibit 13. Apoptosis Related Products – Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Japan, China, India, South Korea and Rest of Asia-Pacific in US$ Million	19
Exhibit 14. Apoptosis Related Products – Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Japan, China, India, South Korea and Rest of Asia-Pacific	20
3.5 (I) Japanese Apoptosis Related Products Market	20
3.5 (II) Australian Apoptosis Related Products Market	20
3.5 (III) Chinese Apoptosis Related Products Market	20
3.5 (IV) Indian Apoptosis Related Products Market	20
3.5 (V) South Korean Apoptosis Related Products Market	21
Exhibit 15. List of Major Asia-Pacific Companies	21
3.6 Rest of World Apoptosis Related Products Market	22
Exhibit 16. Apoptosis Related Products – Rest of World Market Estimations & Predictions (2005 - 2020) by Country for Brazil, Israel, South Africa and Other Countires in US$ Million	22
Exhibit 17. Apoptosis Related Products – Rest of World Market Shares (2010, 2015 & 2020) by Country for Brazil, Israel, South Africa and Other Countries	23
3.6 (I) Brazilian Apoptosis Related Products Market	23
3.6 (II) Israeli Apoptosis Related Products Market	23
3.5 (III) South African Apoptosis Related Products Market	23
Exhibit 18. List of Major Rest of World Companies	23
3.7 Company Profiles - Major Players in Apoptosis Market	24
A.G. Scientific, Inc. (USA)	24
AbbVie, Inc. (USA)	24
AbGenomics International, Inc. (USA)	25
Aegera Therapeutics, Inc. (Canada)	26
Æterna Zentaris, Inc. (Canada)	27
Amarantus BioScience Holdings, Inc. (USA)	28
Anavex Life Sciences Corporation (USA)	29
Aposense Ltd. (Israel)	30
ArQule, Inc. (USA)	30
Ascenta Therapeutics, Inc. (USA)	32
Astellas Pharma, Inc. (USA)	32
Bayer Pharma AG (Germany)	33
BD Biosciences (USA)	34
BioLineRx Ltd. (Israel)	34
Bioniche Life Sciences, Inc. (Canada)	36
BioVision, Inc. (USA)	37
CASI Pharmaceuticals, Inc. (USA)	40
Chroma Therapeutics Ltd. (UK)	40
Cleveland Bio Labs, Inc. (USA)	41
Clontech Laboratories, Inc. (USA)	43
Critical Outcome Technologies, Inc. (Canada)	45
Cyclacel Pharmaceuticals, Inc. (USA)	50
D-Pharm Ltd. (Israel)	50
EMD Millipore (USA)	52
Exelixis, Inc. (USA)	54
F.Hoffmann-La Roche Ltd. (Switzerland)	55
GANYMED Pharmaceuticals AG (Germany)	55
Genentech, Inc. (USA)	56
Genmab A/S (Denmark)	57
Immune Pharmaceuticals, Inc. (USA)	58
ImmunoChemistry Technologies, LLC (USA)	58
Incyte Corporation (USA)	60
Institute of Cancer Research (ICR) (The) (UK)	60
Life Technologies Corporation (USA)	61
MEI Pharma, Inc. (USA)	62
MorphoSys AG (Germany)	62
multimmune GmbH (Germany)	63
Neuren Pharmaceuticals Limited (New Zealand)	63
Novartis AG (Switzerland)	64
Pfizer, Inc. (USA)	65
Pharmacyclics, Inc. (USA)	66
Sigma-Aldrich Co. LLC (USA)	66
Sunesis Pharmaceuticals, Inc. (USA)	68
Takeda Pharmaceutical Co., Ltd. (Japan)	70
Tamir Boitechnology, Inc. (USA)	71
TetraLogic Pharmaceuticals (USA)	72
Teva Pharmaceutical Industries Ltd. (Israel)	73
Tragara Pharmaceuticals, Inc. (USA)	74
ZELTIQ Aesthetics, Inc. (USA)	75
3.8 Recent Activities in Apoptosis Market	76
Genprex Initiates Phase II Clinical Trial for Lung Cancer	76
Can-Fite Gains EU Patent for Liver Treatment Post Surgery	76
Boehringer Ingelheim's Volasertib, an Investigational Oncology Compound, Receives Orphan Drug Designation for AML in the US and EU	76
MaxHealthLabs Develops New Supplement, Intra-Cellular Liposomal Curcumin for Prostate Cancer Treatment	77
Astellas’ XTANDI® Capsules Gains Approval for Marketing as a Prostate Cancer Treatment in Japan	77
BioLineRx Attains Orphan Drug Status for BL-8040, the New Stem Cell Mobilization Therapy	78
Amarantus In-Licenses MANF-related Intellectual Property from University of Massachusetts Medical School	78
Amarantus Enters into Exclusive Option Agreement to License Intellectual Property of Bascom Palmer Eye Institute of the University of Miami to Treat Retinal Diseases Utilizing MANF and CDNF	79
FDA Grants Fast Track Status to VB-111, the Lead Compound of VBL Therapeutics	79
FDA Grants Additional Regulatory Exclusivity for TREANDA® (Bendamustine HCI) for Injection	79
Immune Pharmaceuticals and EpiCept Corporation Merge	80
Techne Corp., Acquires Bionostics Holdings Ltd.	80
Senesco Announces Results of Sns01-T Phase 1b/2a Trial	81
VBL Therapeutics Announces Vb-111 Anti-Angiogenic Gene Therapy Phase I/II Trials	81
Cleveland Biolabs and Incuron Receives US and European Patent Allowances for Curaxins	81
Arqule Regains Global Rights to AKT Program	82
Myriad and PharmaMar Enter into Commercial Agreement with Myriad's New HRD Test	82
CRT and ICR Enter into Collaboration with Janssen for MM Drug Discovery	82
Abbott Diversifies Research-Based Pharmaceuticals Business	83
Clinical Trial of ‘Master Switch’ Drug for Treatment of Diverse Types of Cancers Launched	83
4SC Granted Vital European Patent for Anti-cancer Compound, Resminostat	83
Amarantus BioScience Buys Power3 Medical Products’ Neurodegenerative Diagnostic IP Portfolio	84
4SC Discovery and BioNTech Enter into Research and License Agreement for 4SC's TLR Agonists for Cancer Immunotherapy	84
Aposense Completes Phase 2 Trial with ML-10, Announces Results	85
COTI-2 Observed to Rectify Specific p53 Gene Mutation	85
Pfizer Completes Nutrition Business Sale to Nestle	85
Pfizer Acquires NextWave Pharmaceutical Inc.	86
Belinostat Granted EU Orphan Drug Status for the Treatment of Peripheral T-cell Lymphoma	86
4SC Discovery Granted Euro 600,000 to Develop Personalized Cancer Drugs	86
4SC Granted Patent for Anti-cancer Compound Resminostat in China	86
Critical Outcome Technologies Gets Vital New Mechanism of Action Data for COTI‐2	87
Pfizer and Hisun Launch, Hisun-Pfizer Pharmaceuticals Co., Ltd	87
Genmab Enters into Worldwide Agreement with Janssen for Daratumumab	88
Cleveland BioLabs Enters into US$ 4 Million Contract with Russian Ministry of Industry and Trade for Development of CBLB612	88
FDA Grants Orphan Drug Status to SNS01-T for Treatment of Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma	89
Takeda Acquires URL Pharma, Inc.	89
AbGenomics International Raises US$ 11 Million to Advance Therapeutic Antibodies for Autoimmune Diseases and Cancers	89
Roche Applied Science Launches the E-Plate Insert for Analysis of Cell-Cell Interactions Utilizing the xCELLigence System	90
Affymetrix Acquires eBioscience	90
Exelixis Enters into NCI-CTEP Collaboration for Cabozantinib Development Program	90
Yakult Honsha, Partner of 4SC in Japan, Commences Clinical Development of Anti-cancer Compound Resminostat	91
Abbott to Acquire Action Pharma's Investigational Compound, AP214, in Phase 2b Development for Prevention of Acute Kidney Injury	91
Cellceutix and Beth Israel Deaconess Medical Center Enter into Collaboration for Pro-Apoptotic Function of p53 in Melanoma and Renal Cell Carcinoma	92
Cleveland BioLabs Intiates Advanced Cancer Trial for CBLB502	92
4SC Obtains Patent for its Oncology Compound Resminostat in Taiwan and Three Other Asian Markets	93
FDA Recognizes Subcutaneous Administration of Velcade® In All The Approved Indications	93
Marshall Edwards Received Patent for New Protocol for Usage of ME-344	93
Aeterna Zentaris Enters into Collaboration with Ventana Medical Systems	94
Marshall Edwards Receives New Method of Use Patent for ME-344	94
Exelixis Enters into Licensing Agreement with Merck	94
Pharmacyclics Focus on the Development and Commercialization of PCI-32765, with Janssen Biotech, Inc.	95
Teva Acquires Cephalon	96
WuXi PharmaTech Acquires Abgent	96
Debiopharm and Ascenta Therapeutics in Exclusive Licensing Agreement to Develop and Commercialize Inhibitor of Apoptosis Protein (IAP) Inhibitor AT-406 to Treat Tumors	96
Senesco Signs Agreement with Mayo Clinic for the Study of SNS01-T in Multiple Myeloma	97
Sunesis Pharmaceuticals Receives U.S. Patent Covering Vosaroxin Use to Treat Leukemia	97
Eisai Launches Anticancer Agent Halaven®	98
Harbor Biosciences Enters Into an Umbrella Distribution Collaboration with China Institute of Pharmaceutical Industry (CIPI)	98
Abcam Acquires MitoSciences	98
Pharmascience Acquires Aegera Therapeutics Inc	99
Amarantus BioSciences and Generex Biotechnology Enter Collaboration Agreement	99
R&D Systems Acquires Assets of Boston Biochem	99
Poland based Selvita Inks an Agreement with US based IPD on Computational Chemistry Services Offerings	100
Incyte Gains Milestone Payments of US$ 15 Million for c-MET Inhibitor Oncology Program from Novartis	101
Cephalon Inc Takes Over Chemgenex Pharmaceuticals Limited	101
The Possession of Biovex by Amgen	101
CRT, ICR and ZoBio BV Have Signed a Deal to Develop Cancer Drugs	101
BD Completes Acquisition of Accuri Cytometers, Inc…..	102
Cell Therapeutics Inc. Acquires Exclusive Marketing and Co-Development Rights in North, Central and South America to Tosedostat of Chroma Therapeutics Ltd. This is a First in Class Tumor Selective Oral Therapy for Treatment of Blood Related and Other Cancers	102
Amgen Acquires BioVex	104
US$38.4 Million NHMRC Program Grants Extend Cancer and Blood Cell Research	104
BD Acquires Accuri Cytometers Inc.,	104
Cephalon in Recommended Takeover Bid for ChemGenex Pharmaceuticals Limited	105
Saic-Frederick Selected Aphios Corporation for Building up Camposomes™ on Behalf of National Cancer Institute’s Alliance for Nanotechnology in Cancer	105
Joyant’s Licensed Smac Mimetics Technology Attains US Patent Protection	105
An Agreement Signed by Novartis and Genoptix, inc. for Acquiring the Latter Products in a Cash Offer	106
BioVision Launches Three Novel Assay Kits	107
Novus Biologicals Discovers TIGAR Antibody	108
Novus Biologicals Introduces RBBP6 Antibodies	108
Cleveland BioLabs Obtains $1.6 Million Development Contract from Defense Threat Reduction Agency of Department of Defense for CBLB502	108
Novus Biologicals Launches Novel SIRT1 Antibody based on Genomic Antibody Technology™	109
Senesco Technologies Announces IND Filing for SNSO1-T	109
Cayman Launches Glutathione Cell-Based Detection Kit	110
Cleveland BioLabs Accepts USD 1.6 Million Development Agreement from Defense Threat Reduction Agency Of Department Of Defense For CBLB502	110
FDA Grants Orphan Drug Status to Senesco Technologies’ SNS01 –T	111
Sunesis Pharmaceuticals’ Initiate Phase 3 Valor Trial of Vosaroxin	111
Eli Lilly Suspends Phase III Clinical Trials of Tasisulam	112
EpiCept Initiates Phase II Clinical Trials of CrolibulinTM for Anaplastic Thyroid Cancer	112
Human Genome Sciences and GSK Receives FDA Extension of Benlysta® PDUFA	112
Ascenta Therapeutics Signs R&D Collaboration with Ascentage Pharma	113
Ascenta Therapeutics Enters into Agreement with the Leukemia & Lymphoma Society	113
Telik Reports Final Positive Phase 2 Results of Ezatiostat Hydrochloride (Telintra®/TIK 199)	113
ZELTIQ™ Introduces CoolSculpting	114
Sunesis Receives Major US Patent Covering Vosaroxin Clinical Formulation	114
Roche Signs Collaboration Agreement with Aposense	115
FDA Grants Orphan Drug Status to CBLB502	115
ICT Receives Federal Qualified Therapeutic Discovery Project Grants	116
AbD Serotec Obtains International License to Research Antibody from the Institute of Cancer Research	116
Critical Outcome Technologies Inc. Obtained United States Patent for Oncology Compound COTI-2	117
Celgene Acquires Abraxis BioSciences	117
Rosetta Genomics Identifies Potential MicroRNA Drug Target for Hepatocellular Carcinoma	117
South Africa & EAPO Grants Patent for Protectan CBLB612	117
Cleveland BioLabs Issued With Notice of Patent Allowance from China for CBLB502	118
Consulate General of Canada Selects Critical Outcome Technologies for Life Sciences Partnering Mission	118
Cleveland BioLabs CBLB502 Awarded with USD 45 Million Contract by Department of Defense	119
EntreMed Secures USD 5.1 Million in Registered Direct Offering	119
Pfizer Provides $5 Million to Fund Cancer Treatment Drug of TetraLogic	120
Cleveland BioLabs Reports Results from Second Safety Study for CBLB502	120
Cayman Launches Novel Multi-Parameter Apoptosis Assay Kit	121
CBLB502 Receives Fast Track Status from the FDA	121
Amarantus Therapeutics Receives European Patent Notification of Allowance	121
Conatus Pharmaceuticals Acquires Pfizer’s Idun Subsidiary	122
Sunesis Granted European Patent for Voreloxin	122
Aeterna Zentaris Receives Orphan Drug Status Perifosine	122
Amarantus Enters into Partnership with Pioneer Valley Life Sciences Institute	123
Ascenta Therapeutics Enters Into License Agreement with Sanofi-Aventis	123
Cellceutix Reports Positive Results of Kevetrin	124
FDA Grants Fast Track Status to Antisoma’s AS1413	124
ARIAD and Merck Restructure Collaboration for Ridaforolimus mTOR inhibitor	124
COTI Receives Favorable Independent Pre-Investigational Novel Drug GAP Analysis Report	125
Amarantus Therapeutics Receives Research Grant from Michael J Fox Foundation	125
Yondelis® Approved for Reimbursement in the UK	126
QIAGEN Acquires SABiosciences	126
VisEn Launches Novel Annexin-Vivo 750 Fluorescence Molecular Imaging Agent	126
European Commission Approves Yondelis® for Ovarian Cancer	127
Merck and Schering-Plough Accomplish Merger	127
IBA and Aposense Enter into Marketing Agreement	127
FDA Accepts PharmaMar as Manufacturer of Active Yondelis	128
Marshall Edwards In-Licenses Anti-cancer compound, NV-128 from Novogen Limited	128
OXiGENE Takes Over Symphony ViDA	129
Clinical Data Acquires Avalon Pharmaceuticals	129
Bayer Enters into International Contract with the Ardea	129
Enzo Biochem Acquires Assay Design	130
Eli Lily Completes Acquisition of Imclone Systems	130
Neuren Pharmaceuticals to Receive US$5.5M Additional Funding	131
Thermo Fisher Scientific Takes Over Affinity BioReagents	131
Takeda Acquires Millennium Pharmaceuticals	132
FDA Approves Cephalon’s TREANDA for Chronic Lymphocytic Treatment	132
Eisai Acquires MGI Pharma	132
Human Genome Sciences and Aegera Therapeutics Enter into Licensing Partnership	132
EntreMed Announces Results for ENMD-1198 and Vincristine in Pre-clinical Leukemia Models	133
Arius Signs Agreement with Avid Bioservices for CD44 Cancer Stem Cell Antibody	133
AnaSpec Launches Bcl Peptides	133
BioLineRx Acquires the Anti-Cancer Compound BL-4060	134
Cell Signaling Technology Offers PhosphoScan® Profiling Technology and PhosphoSite® Knowledgebase to Academic Researchers	134
Cambridge Antibody Technology Merges into MedImmune	134
Human Genome Sciences Shows Anti-Tumor Activity and Efficacy of TRAIL Receptor Antibodies When Combined with Chemotherapy	135
ImClone and Bristol-Myers Squibb Form an Agreement with Merck KGaA to Jointly Develop and Commercialize ERBITUX® in Japan	135
Cyclacel Pharmaceuticals Buys Specialty Pharmaceutical Business Focused on the Oncology Market	135
EpiCept Successfully Completes Phase I Trial for EPC2407 in Apoptosis Induction	136
Aegera Therapeutics Acquires LymphoSign Inc and Closes Concurrent Financing	136
Genentech Buys Stake in Tanox	137
Cell Signaling Technology Inc., Increases its PhosphoScan® Patent Portfolio	137
TopoTarget Acquires Apoxis SA	137
Myriad Genetics and AstraZeneca Collaborate on New Treatment for BRCA1 & BRCA2 Mutations	138
Azixa™ of Myriad Genetics in Phase II for Brain Cancer	138
Takeda Pharmaceuticals and CanBas in Collaboration for Cancer Treatment	138
BD Biosciences Collaborates with Roche to Accelerate the Study of Cell Signal Transduction Using New Phosphorylation Site Antibody Targets and Applications	138
MMRC Joins Hands with Keryx	139
3.9 Analysis by Molecular Pathways	140
Exhibit 19. Apoptosis by Molecular Pathways – Global Market Estimations & Predictions (2005 - 2020) for Caspase Activators and Inhibitors, Protease Inhibitors, Bcl-2 Modulators, p53 Modulators and Other in US$ Million	140
Exhibit 20. Apoptosis by Molecular Pathways – Global Market Shares (2010, 2015 & 2020) for Caspase Activators and Inhibitors, Protease Inhibitors, Bcl-2 Modulators, p53 Modulators and Other	141
3.9.1 Global Apoptosis Caspase Activators and Inhibitors Market	142
Caspases	142
Market Analysis	142
Exhibit 21. Caspase Activators and Inhibitors - Global Market Estimations & Predictions (2005 -2020) by Country for North America, Europe, Asia-Pacific and Rest of World in US$ Million	143
Exhibit 22. Caspase Activators and Inhibitors - Global Market Shares (2010, 2015 & 2020) by Country for North America, Europe, Asia-Pacific and Rest of World	144
3.9.1 (I) North American Apoptosis Caspase Activators and Inhibitors Market	144
3.9.1 (II) European Apoptosis Caspase Activators and Inhibitors Market	144
3.9.1 (III) Asia-Pacific Apoptosis Caspase Activators and Inhibitors Market	144
3.9.1 (IV) Rest of World Apoptosis Caspase Activators and Inhibitors Market	144
Analysis by Application	145
3.9 (a) Drugs	145
Exhibit 23. Drugs (Caspase Activators & Inhibitors) - Global Value Market Estimations & Predictions (2011 -2018) by Geographic Regions for North America, Europe, Asia-Pacific and Rest of World in US$ Million	145
Exhibit 24. Drugs (Caspase Activators & Inhibitors) - Global Value Market Shares (2011 & 2018) by Geographic Regions for North America, Europe, Asia-Pacific and Rest of World	146
3.9 (b) Diagnostics	147
Exhibit 25. Diagnostics (Caspase Activators & Inhibitors) - Global Value Market Estimations & Predictions (2011 -2018) by Geographic Regions for North America, Europe, Asia-Pacific and Rest of World in US$ Million	147
Exhibit 26. Diagnostics (Caspase Activators & Inhibitors) - Global Value Market Shares (2011 & 2018) by Geographic Regions for North America, Europe, Asia-Pacific and Rest of World	148
3.9 (c) Laboratory Reagents	149
Exhibit 27. Laboratory Reagents (Caspase Activators & Inhibitors) - Global Value Market Estimations & Predictions (2011 -2018) by Geographic Regions for North America, Europe, Asia-Pacific and Rest of World in US$ Million	149
Exhibit 28. Laboratory Reagents (Caspase Activators & Inhibitors) - Global Value Market Shares (2011 & 2018) by Geographic Regions for North America, Europe, Asia-Pacific and Rest of World	150
3.9.2 Global Apoptosis Protease Inhibitors Market	151
Market Analysis	151
Exhibit 29. Protease Inhibitors - Global Market Estimations & Predictions (2005 -2020) by Country for North America, Europe, Asia-Pacific and Rest of World in US$ Million	152
Exhibit 30. Protease Inhibitors - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	153
3.9.2 (I) North American Apoptosis Protease Inhibitors Market	153
3.9.2 (II) European Apoptosis Protease Inhibitors Market	153
3.9.2 (III) Asia-Pacific Apoptosis Protease Inhibitors Market	153
3.9.2 (IV) Rest of World Apoptosis Protease Inhibitors Market	153
3.9.3 Global Apoptosis Bcl-2 Modulators Market	154
The Role of Bcl-2 in Diseases	154
Market Analysis	154
Exhibit 31. Bcl-2 Modulators - Global Market Estimations & Predictions (2005 -2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	155
3.9.3 (I) North American Apoptosis Bcl-2 Modulators Market	156
3.9.3 (II) European Apoptosis Bcl-2 Modulators Market	156
3.9.3 (III) Asia-Pacific Apoptosis Bcl-2 Modulators Market	156
3.9.3 (IV) Rest of World Apoptosis Bcl-2 Modulators Market	156
3.9.4 Global Apoptosis p53 Modulators Market	157
Market Analysis	157
Exhibit 33. p53 Modulators - Global Market Estimations & Predictions (2005 -2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	158
Exhibit 34. p53Modulators - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	159
3.9.4 (I) North American Apoptosis p53 Modulators Market	159
3.9.4 (II) European Apoptosis p53 Modulators Market	159
3.9.4 (III) Asia-Pacific Apoptosis p53 Modulators Market	159
3.9.4 (IV) Rest of World Apoptosis p53 Modulators Market	159
3.9.5 Global Other Apoptosis Molecular Pathways	160
Exhibit 35. Other Apoptosis Molecular Pathways - Global Market Estimations & Predictions (2005 -2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	160
Exhibit 36. Other Apoptosis Molecular Pathways - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	161
3.10 Analysis by Therapeutic Areas	162
Exhibit 37. Apoptosis based Therapeutics – Global Market Estimations & Predictions (2005 - 2020) for Cancer, Neurodegenerative, Cardiovascular and Other in US$ Million	162
Exhibit 38. Apoptosis based Therapeutics – Global Market Shares (2010, 2015 & 2020) for Cancer, Neurodegenerative, Cardiovascular and Other	163
3.10.1 Global Market for Apoptosis based Cancer Therapeutics	164
Cancer	164
Role of Apoptosis Proteins and Genes in Cancer	164
Bcl-2 Modulators	164
IAPs	164
Market Analysis	164
Exhibit 39. Apoptosis based Cancer Therapeutics - Global Market Estimations & Predictions (2005 -2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	165
Exhibit 40. Apoptosis based Cancer Therapeutics - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	166
3.10.1 (I) North American Market for Apoptosis based Cancer Therapeutics	166
3.10.1 (II) European Market for Apoptosis based Cancer Therapeutics	166
3.10.1 (III) Asia-Pacific Market for Apoptosis based Cancer Therapeutics	166
3.10.1 (IV) Rest of World Market for Apoptosis based Cancer Therapeutics	166
3.10.2 Global Market for Apoptosis based Neurodegenerative Diseases’ Therapeutics	167
Exhibit 41. Apoptosis based Neurodegenerative Diseases’ Therapeutics - Global Market Estimations & Predictions (2005 -2020) by Geographic Region for North America, Europe,  Asia-Pacific and Rest of World in US$ Million	167
Exhibit 42. Apoptosis based Neurodegenerative Diseases’ Therapeutics - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	168
3.10.2 (I) North American Apoptosis based Neurodegenerative Diseases’ Therapeutics Market	168
3.10.2 (II) European Apoptosis based Neurodegenerative Diseases’ Therapeutics Market	168
3.10.2 (III) Asia-Pacific Apoptosis based Neurodegenerative Diseases’ Therapeutics Market	168
3.10.2 (IV) Rest of World Apoptosis based Neurodegenerative Diseases’ Therapeutics Market	168
3.10.3 Global Apoptosis Market for based Cardiovascular Diseases Therapeutics	169
Exhibit 43. Apoptosis based Cardiovascular Diseases Therapeutics - Global Market Estimations & Predictions (2005 -2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	169
Exhibit 44. Apoptosis based Cardiovascular Diseases Therapeutics - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	170
3.10.3 (I) North American Apoptosis based Cardiovascular Diseases Therapeutics Market	170
3.10.3 (II) European Apoptosis based Cardiovascular Diseases Therapeutics Market	170
3.10.3 (III) Asia-Pacific Apoptosis based Cardiovascular Diseases Therapeutics Market	170
3.10.3 (IV) Rest of World Apoptosis based Cardiovascular Diseases Therapeutics Market	170
3.10.4 Global Market for Apoptosis based Other Therapeutic Products	171
Exhibit 45. Apoptosis based Other Therapeutic Products - Global Market Estimations & Predictions (2005 -2020) by Geographic Region for North America, Europe,  Asia-Pacific and Rest of World in US$ Million	171
Exhibit 46. Apoptosis based Other Therapeutic Products - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	172
3.11 Analysis by Imaging/Detection Technologies for Cancer	173
Apoptosis Imaging/Detection Technologies	173
Exhibit 47. Apoptosis Imaging/Detection Technologies for Cancer – Global Value Market Estimations & Predictions (2005 - 2020) for Molecular Imaging, Optical Imaging, Flow Cytometry and Other^ Imaging Technologies in US$ Million	174
Exhibit 48. Apoptosis Imaging/Detection Technologies for Cancer – Global Value Market Shares (2010, 2015 & 2020) for Molecular Imaging, Optical Imaging, Flow Cytometry and Other Imaging Technologies	175
3.11.1 Global Market for Molecular Imaging Technologies for Apoptosis in Cancer	176
Molecular Imaging	176
PET	176
SPECT	176
Magnetic Resonance Imaging	176
Market Analysis	177
Exhibit 49. Molecular Imaging Technologies for Apoptosis in Cancer – Global Market Estimations & Predictions (2005 - 2020) for North America, Europe, Asia-Pacific and Rest of World in US$ Million	178
Exhibit 50. Molecular Imaging Technologies for Apoptosis in Cancer – Global Market Shares (2010, 2015 & 2020) for North America, Europe, Asia-Pacific and Rest of World	179
3.11.1 (I) North American Market for Molecular Imaging Technologies for Apoptosis in Cancer	179
3.11.1 (II) European Market for Molecular Imaging Technologies for Apoptosis in Cancer	179
3.11.1 (III) Asia-Pacific Market for Molecular Imaging Technologies for Apoptosis in Cancer	179
3.11.1 (IV) Rest of World Market for Molecular Imaging Technologies for Apoptosis in Cancer	179
3.11.2 Global Market for Flow Cytometry for Apoptosis in Cancer	180
Detection of Molecules Involved in Apoptotic Death	180
Cell Cycle Analysis	180
Caspase Activity Determination	180
Market Analysis	180
Exhibit 51. Flow Cytometry Technologies for Apoptosis in Cancer – Global Market Estimations & Predictions (2005 - 2020) for North America, Europe, Asia-Pacific and Rest of World in US$ Million	181
Exhibit 52. Flow Cytometry Technologies for Apoptosis in Cancer – Global Market Shares (2010, 2015 & 2020) for North America, Europe, Asia-Pacific and Rest of World	182
3.11.2 (I) North American Market for Flow Cytometry Technologies for Apoptosis in Cancer	182
3.11.2 (II) European Market for Flow Cytometry Technologies for Apoptosis in Cancer	182
3.11.2 (III) Asia-Pacific Market for Flow Cytometry Technologies for Apoptosis in Cancer	182
3.11.2 (IV) Rest of World Market for Flow Cytometry Technologies for Apoptosis in Cancer	182
3.11.3 Global Market for Optical Imaging Technologies for Apoptosis in Cancer	183
NIR Tracers	183
Market Analysis	183
Exhibit 53. Optical Imaging Technologies for Apoptosis in Cancer – Global Market Estimations & Predictions (2005 - 2020) for North America, Europe, Asia-Pacific and Rest of World in US$ Million	184
Exhibit 54. Optical Imaging Technologies for Apoptosis in Cancer – Global Market Shares (2010, 2015 & 2020) for North America, Europe, Asia-Pacific and Rest of World	185
3.11.3 (I) North American Market for Optical Imaging Technologies for Apoptosis in Cancer	185
3.11.3 (II) European Market for Optical Imaging Technologies for Apoptosis in Cancer	185
3.11.3 (III) Asia-Pacific Market for Optical Imaging Technologies for Apoptosis in Cancer	185
3.11.3 (IV) Rest of World Market for Optical Imaging Technologies for Apoptosis in Cancer	185
3.11.4 Global Market for Other Imaging Technologies for Apoptosis in Cancer	186
Fluorescence Microscopy	186
Ultrasound	186
Exhibit 55. Other Imaging Technologies for Apoptosis in Cancer – Global Market Estimations & Predictions (2005 - 2020) for North America, Europe, Asia-Pacific and Rest of World in US$ Million	187
Exhibit 56. Other Imaging Technologies for Apoptosis in Cancer – Global Market Shares (2010, 2015 & 2020) for North America, Europe, Asia-Pacific and Rest of World	188
3.12 Apoptosis - Market Outlook	189
4. PRODUCT/TECHNOLOGY RESEARCH	190
4.1 Introduction	190
Apoptosis – The Major Form of Programmed Cell Death	190
Morphological Characteristics of Apoptosis	190
Apoptosis in Relation to Health & Disease	191
Apoptosis Pathway	192
Extrinsic Pathway	192
Intrinsic Mitochondrial Pathway	193
Role of Nitric Oxide in Apoptosis	193
Apoptosis and the Immune System	194
Regulatory Mechanisms in Apoptosis Signaling	195
Regulation of Apoptosis by IAPS (Inhibitors of Apoptosis Proteins)	195
Importance of Apoptosis	196
The Process of Apoptosis	197
Cell Death Due to Injury	197
Cell Death Due to Suicide	197
Reasons for Cell Suicide	198
1. Apoptosis is an eminent requisite for systematic enhancement of mitosis:	198
2. Apoptosis is required to eliminate cells that pose danger to the union of organism:	198
a. Apoptosis stimulated by internal signals: The internal or mitochondrial pathways:	198
b. Triggering of death activators that binds the receptors on the cell surface:	199
c. Apoptosis-Inducing Factor (AIF)	199
Apoptosis Procedure	199
Initiation Phase	200
Execution Phase	200
Elimination Phase	201
4.2 Apoptosis Molecular Pathways	201
Key Molecular Pathways of Apoptosis	201
Caspases	202
Types of Caspase Proteins	202
Initiator Caspases	202
Effector Caspases	202
The Caspase Flow	202
Function of Caspases in Apoptosis, Development and Cytokine Maturation	203
Card Domains	203
Imaging Caspase Activity	204
Direct Imaging of Caspases	204
Activatable Probes for Caspases	204
Reporter Gene Imaging of Caspase Activity	205
Imaging Mitochondrial Membrane Potential	206
Protease Inhibitors	208
Bcl-2 Modulators	208
Structure of Bcl-2 Family	209
The Role of Bcl-2 in Diseases	209
Biochemical Properties of Bcl-2 Proteins	210
Cytoplasmic Proteins	210
p53 Modulators	210
Other Apoptosis Molecular Pathways	211
Inhibitors of Apoptosis Proteins	211
Identification of IAP Gene Family Proteins	212
TRAIL	213
MLK Inhibitor	214
Factor 5A	215
Protein Kinase Pathway Modulators	215
Chemotherapeutic Role of Telcyta in Various Cancers	215
Nicotinic Acetylcholine Receptor Agonist	216
HSP27	217
4.3 Disease Areas Connected with Apoptosis	217
Cancer	218
Major Companies in Global Cancer Market	218
Exhibit 57. Global Market for Cancer Therapeutic Products (2012): Percentage Breakdown of Market Share for Top 10 Companies	218
Neurodegenerative Disease	218
Alzheimer’s Disease	218
Importance of Apoptosis in Alzheimer’s Disease	219
Familial Alzheimer's Disease and Role of Mutant APP	219
Parkinson’s Disease	219
Function of Apoptosis in PD and Symptoms of Neuronal Degradation	220
Apoptosis in Parkinson's Disease and Nigral Neuronal Death	221
Potential Markers of Apoptosis in Parkinson's Disease	221
Rheumatoid Arthritis	222
Role of Apoptosis in Rheumatoid Arthritis Synovium	222
Multiple Sclerosis	223
The Diagnosis of MS	223
Functioning of Oligodendrocytes Apoptosis in MS and EAE	223
Cardiovascular Diseases – Role of Cell Apoptosis	224
Other Apoptosis Based Diseases	225
Organ Transplant Rejection	225
Types of Organ Rejection	225
Hyperacute Rejection	225
Acute Rejection	225
Chronic Rejection	226
Treating Rejection	226
HIV Infection	226
Sepsis and Multiple Organ Dysfunction Syndrome	227
Requirement of Logical Strategies	227
Sepsis Controlled by Apoptosis	227
4.4 Apoptosis Therapeutics	227
Technologies Involved in Drug Making Process for Apoptosis Based Treatment	227
Target Discovery and Validation	227
Structural Biology	227
Drug Candidate Identification	228
Antisense	228
Types of Antisense	229
The nbl Antisense	229
Antisense CK2	229
Np73 Antisense	229
Np73 Function in SH-SY5Y Neuroblastoma Cells	230
Small Molecule Mimetics	230
Drug Discovery	230
Combinatorial Chemistry	230
High Throughput Screening	231
Analysis of Apoptosis Based Drugs – Listed by Molecular Pathways	232
Caspases	232
Executioner Caspases	232
CASPASE-8	232
Caspase-3	232
IDN-6556	233
Application of IDN-6556 for Human Liver Preservation Injury	234
MX1122	234
MX1013	234
Protease Inhibitors	235
VELCADE™ (BORTEZOMIB)	235
Bcl-2 Modulators	235
Genase	235
Genasense in combination with chemotherapy	236
Genasense: Positive effects on Bladder Tumor	236
HA14-1	236
p53 Modulators	236
SCH58500	236
INGN 241	237
INGN 241 in combination with Introgen	237
Administration of INGN 241 with Herceptin	238
INGN 251	238
ONYX-015	238
Apoptosis Related Products in Developments	238
The Combination of Apoptosis with Anti-Angiogenesis Yields Better Results	238
Personalized Cancer Therapy with Caspase-3	239
Exhibit 58. Sales of Approved Drugs -Apoptosis Inhibitors & Inducers	239
Methods and Technologies for Imaging/Detecting Apoptosis	239
Assays for Apoptosis	240
Membrane Alterations	241
Detection of Apoptosis in Whole Mounts	242
Mitochondrial Assays	242
Application of Luminescent Assays for effective Measurement of Caspase Activity	243
Fluorescent Assays for Measuring Caspase Activity	243
Apo-ONE® Homogeneous Caspase-3/7 Assay	243
Colorimetic Assay for Detecting Caspase Activity	244
FITC-VAD-FMK the newly developed In Situ Marker for Caspase-3	244
Active Caspase-3 Detection by the application of an Antibody	244
Use of Mitochondrial Markers for Cell Death Detection	244
Mitochondrial Dyes and its application to analyze dell death	244
Apoptosis detection by measuring variations in Cell Membrane	245
Apoptosis detection using DNA Fragmentation	245
Multiplexing Assays	246
Imaging Technologies	246
Molecular Imaging	247
Molecular Imaging of Apoptosis in Cancer	249
PET	250
Mechanism of PET	251
Production of [F-18] Fluoroannexin for Imaging Apoptosis with PET	251
SPECT	252
Magnetic Resonance Imaging (NMRI)	252
MRI Imaging of Apoptosis	252
Flow Cytometry Technique for Apoptosis	253
Protein Expression	254
Caspases Activation	254
Alterations in Mitochondrial Membrane Capacity	255
Plasma Membrane Variations	255
Rise in Membrane Permeability	255
DNA Degradation	255
Optical Imaging	256
Optical Imaging of Apoptosis	256
NIR Tracers	256
Other Imaging Technologies	257
Fluorescence Microscopy	257
Apoptosis Imaging Using Fluorescence Microscopy	257
Ultrasound	258
DNA Electrophoresis	258
Microscopy	259
Future Outlook of Imaging Technologies	259
Apoptosis Detection Kit	260
Cell Apoptosis DAPI Detection Kit	260
Main Features	260
Cell Apoptosis PI Detection Kit	261
Caspase 3 Colorimetric Assay Kit	261
Main Features	262
Double Stain Apoptosis Detection Kit	262
Main Features	262
Mitochondrial Apoptosis Detection Kit	263
Main Features	263
TUNEL (TdT-Mediated dUTP Nick-End Labeling) Detection Kits	263
Annexin V-FITC Apoptosis Detection Kit	263
FLICA Apoptosis Detection Kits	264
Apoptosis Reagents	264
The TUNEL Assay	264
Annexin V	264
Imaging of Apoptosis with 99mTc Annexin V	265
Analysis of the therapeutic efficiency of anti-cancer compounds is accelerated by Annexin V	266
Apoptosis	266
Annexin V	267
The advantage of Annexin V when compared to that of DNA laddering and TUNEL assays	267
Imaging	268
Platform of Molecular Imaging	268
Functions of Annexin V	268
Imaging of apoptosis with peptides and small molecules	269
Synaptotagmin	270
FDG	271
Iodine-123	271
4.5 Research Briefs	272
Regulating an Important Cancer-Fighting Protein	272
Carbon Monoxide and Anesthesia-Induced Neuroapoptosis	272
Balance in the Immune System-One molecule produces an Effect on Health	273
New Strategy to Combat resistant tumor cells	274
Zinc Controls an Important Enzyme in Cell Death	274
New Molecule - May help in Immune Disorders, Runaway Inflammation	275
Dying Cells in Fruit Fly Stimulate Neighboring Cells to Protect Themselves	275
Scientists Find new Process to Detect Key Indicator of Heart Diseases	276
ICU Ventilation Bad for Mental Health	276
Biphasic Electrical Simulation - Hope for Spinal Cord Injury Patients	277
New Methods for Tackling High-Risk Leukemia	278
Apoptosis Stimulates Replication of Common Viruses	279
Liver Cancer caused by Chronic Inflammation: Tumor Growth Seen after programmed cell death (apoptosis)	280
Nanometer Scaffolds Regulates Neural Stem Cells Behavior	280
New Drug Combination Discovered for Leukemia Treatment	281
Cancer Cell Metabolism	282
MK-1775: A Potential Therapeutic Against Sarcomas	283
Researchers Capture Key Moments in Cell Death	284
Role of IKBKE in the Onset of Non-Small Cell Lung Cancer	285
Potential Drug Target for Parkinson's Disease Discovered	285
New Chemotherapy Model for Colorectal Cancer Treatment	286
Singaporean Scientists Discover New Biomarker for Cancer in Bone Marrow	287
Causes Underlying Myelodysplastic Syndromes	287
Providing Lithium to Persons Who Require It	288
Immune Cell Death Works against Autoimmune Disease	289
New Substance to Induce Cancer Cell Suicide	289
Elucidating the Action of the Tumor Suppressor Mig6	290
Treatment Acute Liver Failure	291
Plant-based Compound Effective in Controlling Breast Cancer	293
New Way for Inducing Apoptosis	293
New Process Shows Interference during Communication between Two Important Cellular Processes	294
Labeled for Annihilation: Latest Compound that Stimulates Cancer Cell Death	296
Melanoma's Resistance to Vemurafenib Rectified	296
Unraveling the Secrets behind Mitochondrial DNA Defects that Cause Inherited Deafness	297
Deciphering the Mechanism to Prevent Programmed Cell Death of Nerve Cells	298
Cell Death Pathway Associated With Lethal Sepsis Identified	299
Multiple Drug Therapy for Curing Different Forms of Cancer Discovered	299
New Substance that Could Interfere with Protein Waste Could be Used as a New Cancer Drug	300
Preventing Pancreatic Cell Death in type 1 Diabetes	301
Discovery of Key Gene Function Against Cell Death	301
Prevention of Skin Inflammation through the Controlling of Cell Death	302
New Test to Predict Cancer Cells Response to Chemotherapy Using Cells Primed for Apoptosis Developed	304
Understanding Fluke Worm 'Cell Death' Machinery – New Drug Development	305
Newborn Neurons	305
Cells Die to Enable the Defensive Organs to Live	306
New Candidate Compounds Discovered for Treating Breast Cancer	307
Scientist of Scripps Institute Discovers a Novel Way to Block Stress Related Cell Death	308
Scientist Discover Genes that are Required for Effective Cancer Therapy	308
Breast Cancer Can be Treated by an Anti-Inflammatory Drug	309
Stress Response for Self-Destruction of Cancer Cells	311
Common incurable neurodegenerative disease is linked to inherited genes	312
Obatoclax Initiates ATG7-Dependent Autophagy Independent of BACLIN-1 and also BAX/BAK	313
Preoteolytic Degradation of BRCA1 in Ionization-Induced Apoptosis	314
Cancer Cell Senescence Induced by the BH3 Mimetic ABT-737	315
Analysis of Apoptosis Signaling in Pancreatic Cancer by Computational Signal Transduction Analysis	316
The Determination of Various Forms of Transient RNAi during Apoptosis in Mammalian Cells	316
Cord Blood Stem Cell-Mediated Induction of Apoptosis in Glioma down regulates X-Linked Inhibitor of Apoptosis Protein or XIAP	317
Dynamic Computational Model Indicates That Cellular Citizenship Is Very Important for Selective Tumor Apoptosis	318
Noninvasive Molecular Imaging of Apoptosis Using Modified Firefly Luciferase Substrate, Z-Devd-Aminoluciferin to Obtain Therapeutic Efficiency	319
ABL-N Induced Apoptosis in Human Breast Cancer Cells is Partially Mediated by c-Jun NH2- Terminal Kinase Activation	319
Utilization of Reduced Nicotinamide Adenine Dinucleotide (NADH) Fluorescence to Detect Cell Death or Apoptosis	320
In Vivo Apoptosis Imaging Agents and Various Strategies	321
Translational Imaging of Apoptosis	321
Apoptosis in Vivo with Scintigraohic and Optical Biomarkers	322
Molecular imaging of Apoptosis with Radio-Labeled Annexin A5 Focused on the Evaluation of Response of Tumors to Chemotherapy	322
Application of Noninvasive optical imaging of apoptosis using caspase-targeted activity-based probes	323
Thiazole Antibiotics Aim at FoxM1 and Induce Apoptosis in Human Cancer Cells	323
MYC Prevents Apoptosis and Subsequently Enhances Endoreduplication when Induced by Paclitaxel	323
Giuliana Gatti1, Giovanna Maresca2, Manuela Natoli2, Fulvio Florenzano2, Angelo Nicolin1, Armando Felsani2,3*, Igea D'Agnano2A Fat-Rich Diet Induces Apoptosis of Hypothalamic Neurons	324
Mediated Apoptosis and Its Inhibition by Viral Proteins Better Known as MAVS	325
SPECT and PET Imaging of Apoptosis in Extremely Vulnerable Atherosclerotic Plaques Using Radiolabeled Annexin A5	326
The Removal of the Mitochondrial Flavoprotein Apoptosis Inducing Factor (AIF) Induces β-Cell Apoptosis and Damages β-Cell Mass	326
The Role of N-Acetylcholinesterase-Induced Apoptosis in AD or Alzheimer's disease	327
JunB Inhibits Endoplasmic Reticulum Stress and Apoptosis in Pancreatic Beta Cells	328
TAF6δ Inhibits Apoptosis and Gene Expression in the Absence of p53	328
Optical Imaging of TNF-α Induced Apoptosis Pathway in Living PC12 Cells	329
Association of FDG Uptake and Kinetics with Apoptosis Related Gene Expression	329
Ultrasound Biomicroscopy – Apoptosis	330
Imaging apoptosis in vivo applying the substances 24I-annexin V and PET	330
Generation of [F-18] Fluoroannexin for Imaging Apoptosis using PET	331
Optical Imaging of Apoptosis as a Biomarker of Tumor Response to Chemotherapy	331
New Apoptosis Research Method with Imaging - Combined Flow Cytometer and HITC or IR 125 Staining	332
Annexin V-CLIO: A prominent nanoparticle for analyzing and detecting apoptosis by MRI	333
Ultrasonic Biomicroscopy of Viable, Dead and Apoptotic Cells	333
V. CORPORATE DIRECTORY	334
VI. PATENTS INFORMATION	372

To request a free sample copy of this report, please complete the form below.

Enter captcha code*

We never share your personal data. Privacy policy